Compare FIGR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIGR | BLTE |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | 602 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.2B |
| IPO Year | N/A | 2021 |
| Metric | FIGR | BLTE |
|---|---|---|
| Price | $40.50 | $143.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $53.22 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 3.7M | 83.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.23 | N/A |
| Revenue Next Year | $24.25 | $492.11 |
| P/E Ratio | $134.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.01 | $56.68 |
| 52 Week High | $78.00 | $200.00 |
| Indicator | FIGR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 31.93 |
| Support Level | $40.30 | $103.94 |
| Resistance Level | $42.98 | $172.02 |
| Average True Range (ATR) | 3.01 | 5.92 |
| MACD | 0.58 | -1.24 |
| Stochastic Oscillator | 67.34 | 6.08 |
Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.